Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Trader J's Inner Circle -- Ignore unavailable to you. Want to Upgrade?

To: Canuck Dave who wrote (26351)	1/22/2000 3:44:00 PM
From: hoffy	Respond to of 56532

What I like about SSET and the rise is that it has not come all in one day on any news. It's just been a nice steady accumulation over the past 2-3 months with actually very little news. Once news starts coming out on this stock it will already be much higher. I am looking for a steady ride to 20 or so and then a big pop when the story gets going. Most institutions don't even look at these stocks until they are over 10 so SSET should be getting some attention now. With the small float I wouldn't be surprised to see a stock split once it gets to the 25-30 range.

To: Canuck Dave who wrote (26351)	1/22/2000 3:45:00 PM
From: Nicole Bourgault	Respond to of 56532

T.SSB StressGen Biotechnologies Corp - Post says StressGen favoured by Tera Capital StressGen Biotechnologies Corp SSB Shares issued 32,717,227 2000-01-18 close $3.9 Wednesday Jan 19 2000 The Financial Post reports in its Wednesday edition that StressGen Biotechnologies is a top stock pick of Duncan Stewart, a partner at money management firm Tera Capital in Toronto. Buy & Sell columnist Sonita Horvitch notes the stock, recently $3.90, has a 52-week range of $3.90 to $1.20. Mr. Stewart says that StressGen's drugs can cure cervical cancer and anal dysplasia in a non-surgical manner, which is a big plus. Mr. Stewart also says that Stressgen burns less cash than other biotech companies. His 12-month target price on the stock is $10. Overall, Mr. Stewart is looking for the biotechnology sector to lead the technology sector this year and he expects the Canadian tech sector as a whole to do better than its United States counterpart. He says the biotech sector has underperformed the tech stocks for some time and investors are turning to it because the biotech stocks offer value relative to other tech stocks. (c) Copyright 2000 Canjex Publishing Ltd. canada-stockwatch.com